Mitoxantrone is a synthetic anthracenedione antineoplastic and immunomodulatory agent. It functions as a DNA intercalating agent and topoisomerase II inhibitor, leading to DNA strand breaks and apoptosis. In the Indian context, it is a critical component of chemotherapy regimens for acute leukemias, non-Hodgkin's lymphoma, and is also used as a disease-modifying therapy for secondary progressive multiple sclerosis (MS). It is a potent cytotoxic agent with a distinctive blue color and requires careful hematological and cardiac monitoring.
Adult: **Oncology:** 12 mg/m² IV daily for 3 days (in combination with cytarabine for AML) OR 10-14 mg/m² IV every 21 days for NHL. **Multiple Sclerosis:** 12 mg/m² IV every 3 months. Dose is often capped at a maximum single dose of 12-14 mg/m².
Note: **Must be administered as a slow IV infusion over 15-30 minutes.** NEVER as a rapid IV push or bolus. Dilute in at least 50 mL of 0.9% Sodium Chloride Injection or 5% Dextrose Injection. Administer via a free-flowing IV line to avoid extravasation, which can cause severe tissue necrosis. Pre-medication with antiemetics is recommended.
Mitoxantrone exerts its cytotoxic and immunomodulatory effects through multiple mechanisms: 1) Intercalation into DNA, causing structural deformation and inhibition of DNA/RNA synthesis. 2) Inhibition of topoisomerase II, an enzyme critical for DNA replication and repair, leading to protein-associated DNA double-strand breaks. 3) Induction of apoptosis (programmed cell death) in rapidly dividing cells. 4) In multiple sclerosis, it suppresses T-cell, B-cell, and macrophage activity, reducing inflammation and demyelination.
Pregnancy: **FDA Pregnancy Category D.** There is positive evidence of human fetal risk. Can cause fetal harm. Contraindicated in pregnancy. Women of childbearing potential must use effective contraception during and for at least 6 months after therapy. Men should use contraception during and for 3-6 months after therapy.
Driving: May cause fatigue, dizziness, or rarely seizures. Patients should be cautioned about operating machinery or driving if they experience these effects.
| Other Cardiotoxic Agents (e.g., Doxorubicin, Trastuzumab) | Additive risk of cardiomyopathy and CHF. Increases cumulative cardiotoxicity. | Major |
| Myelosuppressive Chemotherapy/Cytotoxic drugs | Profound, prolonged bone marrow suppression. Increased risk of neutropenia, thrombocytopenia, and anemia. | Major |
| Live Vaccines (e.g., MMR, Varicella, Yellow Fever) | Risk of disseminated vaccine-induced infection due to immunosuppression. | Major |
| Allopurinol | May be used to mitigate hyperuricemia from tumor lysis syndrome. No direct harmful interaction. | Moderate (Therapeutic) |
| Cimetidine | May increase mitoxantrone plasma concentrations by inhibiting hepatic enzymes; clinical significance unclear. | Moderate |
Same composition (Mitoxantrone (2mg)), different brands: